A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.

ABSTRACT:

Background

Glioblastoma is the most common primary malignancy of the central nervous system with a dismal prognosis. Genomic signatures classify isocitrate dehydrogenase 1 (IDH)-wildtype glioblastoma into three subtypes: proneural, mesenchymal, and classical. Dasatinib, an inhibitor of proto-oncogene kinase Src (SRC), is one of many therapeutics which, despite promising preclinical results, have failed to improve overall survival in glioblastoma patients in clinical trials. We examined whether glioblastoma subtypes differ in their response to dasatinib and could hence be evaluated for patient enrichment strategies in clinical trials.

Methods

We carried out in silico analyses on glioblastoma gene expression (TCGA) and single-cell RNA-Seq data. In addition, in vitro experiment

SUBMITTER: Alhalabi OT 

PROVIDER: S-EPMC8730774 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature